Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

A research team was looking to make a new anti-inflammatory medication when they found some incredible side effects ...

If Island Pharma’s drug keeps delivering, it could fast-track approval. And in a world with millions of dengue cases a year, ...

Psilocybin, the main psychoactive ingredient in magic mushrooms, could alleviate depression for at least five years after just one dose, according to a new study.

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic ...

Creatine, a naturally occurring compound, enhances athletic performance and shows potential health benefits, but caution and ...

NKGen Biotech has activated two new trial sites in Canada and Florida, US, for the Phase I/IIa study of its cryopreserved expanded autologous natural killer (NK) cell therapy, troculeucel, in patients ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...